Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation

• Published in: International journal of gynecology and obstetrics 2022-08, Vol.158 (2), p.301-307
• Main Authors: Xie, Hui, Wan, Yajun, Yi, Shuijing, Zeng, Fei, Sun, Xin, Yang, Yimin, Xiao, Songshu
• Format: Article
• Language: English
• Subjects: abnormal uterine bleeding; endometrial ablation; NovaSure endometrial ablation
• ISSN: 0020-7292; 1879-3479
• DOI: 10.1002/ijgo.13983

Objective To evaluate the efficiency, postoperative hysterectomy rate, and influencing factors for therapeutic effect of the NovaSure endometrial ablation procedure in abnormal uterine bleeding (AUB). Methods We conducted a retrospective cohort study of 2152 patients from the Department of Gynecology at the Third Xiangya Hospital, CSU from October 2010 to December 2018. Results From the first year to the eighth year after operation, annual effective rate was above 95.24%, and the differences were not statistically significant. There are statistically significant differences between the effective and ineffective groups with regard to age, intrauterine polyps, total length of the uterus, systemic coagulation disorder, and preoperative hemoglobin. A multivariate logistic regression analysis showed that the risk factors associated with systemic coagulation disorders (P = 0.027) and high total uterine length (P = 0.003) affected NovaSure efficacy in the treatment of AUB. By December 2019, the postoperative hysterectomy rate was 1.86% (40/2152) and the complication rate was 1.67% (36/2152). Conclusion NovaSure is a reliable treatment for AUB and serious medical complications because of its simple operation, low amount of bleeding, quick postoperative recovery, and safe and effective short‐term and long‐term efficacy. However, it should be carefully selected for patients with a total uterus length exceeding 10 cm. Treatment of abnormal uterine bleeding by NovaSure endometrial ablation is simple, safe, and effective. Especially, it is suitable for patients with severe medical complications.